Exhibit: ‘Invisible’ Monet, Leon, Was Key to Impressionism

A portrait of Leon Monet by his brother Claude Monet on display as part of an exhibition showcasing the art of Leon Monet, at the Musée du Luxembourg in Paris, Monday, March 13, 2023. (AP)
A portrait of Leon Monet by his brother Claude Monet on display as part of an exhibition showcasing the art of Leon Monet, at the Musée du Luxembourg in Paris, Monday, March 13, 2023. (AP)
TT

Exhibit: ‘Invisible’ Monet, Leon, Was Key to Impressionism

A portrait of Leon Monet by his brother Claude Monet on display as part of an exhibition showcasing the art of Leon Monet, at the Musée du Luxembourg in Paris, Monday, March 13, 2023. (AP)
A portrait of Leon Monet by his brother Claude Monet on display as part of an exhibition showcasing the art of Leon Monet, at the Musée du Luxembourg in Paris, Monday, March 13, 2023. (AP)

Behind some great men, there is a bigger brother.

Claude Monet’s older sibling is the focus of a landmark Paris exhibit illuminating the hitherto unknown role Leon Monet played in the French impressionist painter’s life and art. Leon — a color chemist four years his senior -- is now understood to have been critical in the emergence of Monet’s commercial success as well as the famed color palette that created masterpieces like the "Water Lilies" series.

"It’s never been known before, but without Leon there would not have really been a Monet — the artist the world knows today," said Geraldine Lefebvre, exhibit curator at the Musee du Luxembourg.

"His rich big brother supported him in the first period of his life when he had no money or clients and was starving," she said. "But more than that. The vivid palette Monet was famous for came from the synthetic textile dye colors Leon created" in the town of Rouen — site of some of Claude's best-known paintings.

The groundbreaking exhibit is the fruit of years of investigation by Lefebvre, who visited Monet’s great-grandchildren, studied family albums and brought to light a masterly portrait of Leon by Claude that Leon hid away in a dusty private collection and has never before been seen by the public. The 1874 painting shows Leon with a black suit, stern expression and red — almost wine-flushed — cheeks.

The exhibit dispels a long-held view that Claude and his older brother were estranged.

"Historians always thought the two brothers had nothing to do with each other. It was assumed because there are no photographs of Claude and Leon together, and no correspondence. In reality, they were incredibly close throughout their life," Lefebvre said.

The brothers had an argument in the early 1900s and that may explain why no direct traces of the relationship exist. "Maybe Leon got rid of the traces, maybe it was Claude. Maybe it was jealousy. We will never know. It is a mystery," Lefebvre said.

What is now known is that Leon would wine and dine his younger brother, introduce him to other artists, give him money, and patronize his art — buying it up at auction at high prices to boost his reputation.

"One of the problems was because they shared the surname it seemed like (Claude) Monet was buying back his own pictures. But it was Leon," said professor Frances Fowle, senior curator of French art at the National Galleries of Scotland.

"This exhibit is important as it throws light on Leon Monet, who up until now has been an invisible figure. It also reveals the wider network at work. Leon was a key figure," Fowle added.

Leon’s influence went beyond his brother: He financially supported other impressionists such as Camille Pissarro, Auguste Renoir and Alfred Sisley — some of whom would connect around his dinner table in Rouen. Claude followed his brother to Rouen, where he painted his Rouen cathedral masterpieces.

Monet also worked for his older brother as a color assistant, a pivotal moment not only in his life — but possibly in the emergence of impressionism as we know it.

Leon would dissolve carbon to create a chemical called aniline, which created incredible synthetic colors that natural pigments couldn't compete with. One of the earlier examples of Leon’s color filtering down into Monet’s art is from an 1860s illustration — before he was famous — that is featured in the exhibit. Monet drew his future wife Camille in a dress with an eye-popping green that had never been seen before.

"The French press coined the term ‘Monet green,’" Lefebvre said, adding that journalists were initially mocking of it. "At the time, they said he would make a good dye artist."

However, both Monets had the last laugh.

Claude Monet founded impressionism — a term coined from his 1872 painting "Impression, Sunrise" — to become one of the most celebrated painters of the last two centuries. And by impressionism's height at the end of the 19th century, an incredible "80% of all impressionists’ work" used the synthetic colors borrowed from Leon, according to Lefebvre.

These synthetic hues, which were cutting edge at the time, enabled members of the group to depict the fleeting impression of the moment with shifting colors and luminosity.

"Who knows the exact extent of the impact Leon had on the movement?" Lefebvre said with a shy smile. "But it was extraordinary."

"Leon Monet. Brother of the artist and collector" runs at the Musee du Luxembourg in Paris from March 15 until July 16.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”